Apellis Announces Plans to Submit NDA for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH)
May 21, 2020
Submission of New Drug Application (NDA) planned for second half of 2020 following successful pre-NDA meeting with FDA WALTHAM, Mass., May 21, 2020 –